EA200700718A1 - Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения - Google Patents

Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения

Info

Publication number
EA200700718A1
EA200700718A1 EA200700718A EA200700718A EA200700718A1 EA 200700718 A1 EA200700718 A1 EA 200700718A1 EA 200700718 A EA200700718 A EA 200700718A EA 200700718 A EA200700718 A EA 200700718A EA 200700718 A1 EA200700718 A1 EA 200700718A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kastanospermin
methods
application
compositions containing
combined anti
Prior art date
Application number
EA200700718A
Other languages
English (en)
Inventor
Доминик Дугуа
Original Assignee
Мидженикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мидженикс Инк. filed Critical Мидженикс Инк.
Publication of EA200700718A1 publication Critical patent/EA200700718A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее описание относится в целом к применению кастаноспермина в комбинации с другим терапевтическим агентом для лечения или профилактики инфекций, вызываемых вирусами семейства Flaviviridae или ассоциированных с ними, в частности инфекций, вызываемых вирусом гепатита С (HCV, ВГС) или ассоциированных с ним, а также к применению таких соединений для исследования биологических механизмов инфекции вирусом гепатита С.
EA200700718A 2004-10-06 2005-10-06 Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения EA200700718A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61678704P 2004-10-06 2004-10-06
PCT/CA2005/001528 WO2006037227A1 (en) 2004-10-06 2005-10-06 Combination anti-viral compositions comprising castanospermine and methods of use

Publications (1)

Publication Number Publication Date
EA200700718A1 true EA200700718A1 (ru) 2007-12-28

Family

ID=36142276

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700718A EA200700718A1 (ru) 2004-10-06 2005-10-06 Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения

Country Status (11)

Country Link
US (1) US20060093577A1 (ru)
EP (1) EP1802327A4 (ru)
JP (1) JP2008515816A (ru)
KR (1) KR20070061879A (ru)
CN (1) CN101035555A (ru)
AU (1) AU2005291804A1 (ru)
CA (1) CA2583351A1 (ru)
EA (1) EA200700718A1 (ru)
IL (1) IL182242A0 (ru)
MX (1) MX2007003853A (ru)
WO (1) WO2006037227A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
SI1576138T1 (sl) 2002-11-15 2017-07-31 Idenix Pharmaceuticals Llc 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
EP1853317A2 (en) * 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
JP2009545621A (ja) * 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
JP2010510171A (ja) * 2006-08-21 2010-04-02 ユナイテッド セラピューティクス コーポレーション ウイルス感染症の治療のための併用療法
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
CN101627763A (zh) * 2009-08-26 2010-01-20 中国矿业大学(北京) 植物源昆虫海藻糖酶抑制剂及其应用
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
CN114984030A (zh) * 2022-06-23 2022-09-02 中国人民解放军海军军医大学 利巴韦林在制备抗蜱传脑炎病毒药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) * 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5066807A (en) * 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
US5093501A (en) * 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5959111A (en) * 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
WO2001054692A1 (en) * 2000-01-28 2001-08-02 Synergy Pharmaceuticals, Inc. Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds

Also Published As

Publication number Publication date
KR20070061879A (ko) 2007-06-14
IL182242A0 (en) 2007-09-20
CA2583351A1 (en) 2006-04-13
MX2007003853A (es) 2007-11-21
EP1802327A4 (en) 2009-07-15
JP2008515816A (ja) 2008-05-15
EP1802327A1 (en) 2007-07-04
US20060093577A1 (en) 2006-05-04
WO2006037227A1 (en) 2006-04-13
CN101035555A (zh) 2007-09-12
AU2005291804A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
ATE541844T1 (de) Antivirale verbindungen
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200700243A1 (ru) Способы лечения гепатита с
ATE475660T1 (de) Antivirale verbindungen
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
EA200701669A1 (ru) Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
NO20090453L (no) Hepatitt C Virusinhibitorer
EA201100390A1 (ru) Соединения для лечения гепатита с
BRPI0514176A (pt) inibidores de replicação de hcv
WO2007081517A8 (en) Anti-viral compounds
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
CY1111423T1 (el) Αναστολεις ns5b hcv
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
EA201000277A1 (ru) Соединения для лечения гепатита с
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства